Edgewise Therapeutics, Inc. (EWTX), a muscle disease biopharmaceutical, has several key catalysts to watch in the coming days, with pivotal data expected from its trials of Sevasemten and EDG-7500.
Sevasemten is a first-in-class oral drug designed to target fast skeletal myosin, a key component in muscle contraction. It is aimed at protecting unstable muscles from damage caused by contraction in muscular dystrophies like Becker and Duchenne Muscular Dystrophy (DMD).
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.